Browse

Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer

DC Field Value Language
dc.contributor.authorLim, Hyeong-Seok-
dc.contributor.authorLee, Han Ju-
dc.contributor.authorLee, Keun Seok-
dc.contributor.authorLee, Eun Sook-
dc.contributor.authorJang, In-Jin-
dc.contributor.authorRo, Jungsil-
dc.date.accessioned2010-01-04T04:39:44Z-
dc.date.available2010-01-04T04:39:44Z-
dc.date.issued2007-09-01-
dc.identifier.citationJ Clin Oncol 25:3837-3845en
dc.identifier.issn1527-7755 (Electronic)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17761971-
dc.identifier.urihttps://hdl.handle.net/10371/24832-
dc.description.abstractPURPOSE: The CYP3A and CYP2D6 enzymes play a major role in converting tamoxifen to its active metabolites. CYP3A is a highly inducible enzyme, regulated mainly by pregnane X receptor (PXR). This study assessed the association between genetic polymorphisms of CYP2D6 and PXR, and tamoxifen pharmacokinetics (PK) and clinical outcomes in patients with breast cancer. PATIENTS AND METHODS: Plasma concentrations of tamoxifen and its metabolites were measured. Common alleles of CYP2D6 and PXR were identified in 202 patients treated with tamoxifen 20 mg daily for more than 8 weeks. Twelve of the 202 patients and an additional nine patients with metastatic breast cancer receiving tamoxifen were assessed for clinical outcome in correlation with genotypes. RESULTS: Patients carrying CYP2D6*10/*10 (n = 49) demonstrated significantly lower steady-state plasma concentrations of 4-hydroxy-N-desmethyltamoxifen and 4-hydroxytamoxifen than did those with other genotypes (n = 153; 4-hydroxy-N-desmethyltamoxifen: 7.9 v 18.9 ng/mL, P < .0001; 4-hydroxytamoxifen: 1.5 v 2.6 ng/mL, P < .0001), whereas no difference by PXR genotypes was found. CYP2D6*10/*10 was significantly more frequent among nonresponders with MBC (100% v 50%, P = .0186). In Cox proportional hazard analysis, CYP2D6 genotype and number of disease sites were significant factors affecting time to progression (TTP). The median TTP for patients receiving tamoxifen was shorter in those carrying CYP2D6*10/*10 than for others (5.0 v 21.8 months, P = .0032) CONCLUSION: CYP2D6*10/*10 is associated with lower steady-state plasma concentrations of active tamoxifen metabolites, which could possibly influence the clinical outcome by tamoxifen in Asian breast cancer patients.en
dc.language.isoenen
dc.publisherAmerican Society of Clinical Oncologyen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectBone Neoplasms/secondaryen
dc.subjectBreast Neoplasms/blood/*drug therapy/*geneticsen
dc.subjectCytochrome P-450 Enzyme System/*geneticsen
dc.subjectDisease-Free Survivalen
dc.subjectFemaleen
dc.subjectGenotypeen
dc.subjectHumansen
dc.subjectLiver Neoplasms/secondaryen
dc.subjectLymphatic Metastasisen
dc.subjectMiddle Ageden
dc.subjectPilot Projectsen
dc.subjectPolymorphism, Geneticen
dc.subjectProportional Hazards Modelsen
dc.subjectRespiratory Tract Neoplasms/secondaryen
dc.subjectTamoxifen/*pharmacokinetics/therapeutic useen
dc.titleClinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast canceren
dc.typeArticleen
dc.contributor.AlternativeAuthor임형석-
dc.contributor.AlternativeAuthor장인진-
dc.contributor.AlternativeAuthor노정실-
dc.contributor.AlternativeAuthor이한주-
dc.contributor.AlternativeAuthor이근석-
dc.contributor.AlternativeAuthor이은숙-
dc.identifier.doi10.1200/JCO.2007.11.4850-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Program in Clinical Pharmacology (협동과정-임상약리학전공)Journal Papers (저널논문_협동과정-임상약리학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse